28115-68-6

Usage

Uses

Used in Pharmaceutical Applications:
Pluviatolide is used as a pharmaceutical agent for its diverse biological activities, including antioxidant, enzyme inhibitory, and antispasmodic properties. Its ability to scavenge radicals and inhibit MMP-7 makes it a potential candidate for the development of treatments targeting various diseases and conditions.
Used in Antioxidant Applications:
Pluviatolide is used as an antioxidant agent due to its ability to scavenge ABTS and DPPH radicals. This property can be utilized in the development of antioxidant therapies and supplements to combat oxidative stress and related health issues.
Used in Enzyme Inhibitor Applications:
Pluviatolide is used as an enzyme inhibitor, specifically for its inhibition of matrix metalloproteinase-7 (MMP-7). This application can be beneficial in the development of treatments for conditions where MMP-7 activity is a contributing factor, such as certain types of cancer and inflammatory diseases.
Used in Antispasmodic Applications:
Pluviatolide is used as an antispasmodic agent, as demonstrated by its ability to decrease contractions induced by acetylcholine in isolated guinea pig ileum. This property can be applied in the development of treatments for conditions involving muscle spasms or involuntary contractions, such as irritable bowel syndrome or other gastrointestinal disorders.
Used in Drug Delivery Systems:
In order to enhance the bioavailability and therapeutic outcomes of pluviatolide, novel drug delivery systems can be developed. These systems may involve the use of various organic and metallic nanoparticles as carriers for pluviatolide, aiming to improve its delivery and efficacy in targeted applications.

InChI:InChI=1/C20H20O6/c1-23-18-8-13(2-4-16(18)21)7-15-14(10-24-20(15)22)6-12-3-5-17-19(9-12)26-11-25-17/h2-5,8-9,14-15,21H,6-7,10-11H2,1H3/t14-,15+/m0/s1

Upstream product

• 6302-93-8 5-[Bis(phenylsulfanyl)methyl]-1,3-benzodioxole 
• 84755-36-2 2-(4-benzyloxy-3-methyoxybenzyl)-3-(3,4-methylenedioxybenzyl)-γ-butyrolactone 
• 80483-34-7 4-(1,3-benzodioxol-5-ylmethyl)-4,5-dihydrofuran-2(3H)-one 
• 120-57-0 piperonal 
• 96548-65-1 3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-methoxy-4-oxobutanoic acid 
• 84736-28-7 (methylenedioxy-3,4 benzylidene) α-hemisuccinate de methyle 
• 158665-03-3 (3R,4R,5R)-4-<1,3-Benzodioxol-5-ylbis(phenylthio)methyl>-3-<(4-(benzyloxy)-3-methoxyphenyl)methyl>-5-(l-menthyloxy)dihydro-2(3H)-furanone 
• 33693-48-0 4-benzyloxy-3-methoxybenzyl alcohol 
• 72724-00-6 1-(benzyloxy)-4-(bromomethyl)-2-methoxybenzene 
• 2426-87-1 3-methoxy-4-(phenylmethoxy)benzaldehyde 
• 158705-72-7 (3R,4R)-4-(1,3-Benzodioxol-5-ylmethyl)-3-<(4-(benzyloxy)-3-methoxyphenyl)methyl>dihydro-2(3H)-furanone 

Relevant academic research and scientific papers

Design and synthesis of novel arctigenin analogues for the amelioration of metabolic disorders

Analogues of the natural product (-)-arctigenin, an activator of adenosine monophosphate activated protein kinase, were prepared in order to evaluate their effects on 2-deoxyglucose uptake in L6 myotubes and possible use in ameliorating metabolic disorders. Racemic arctigenin 2a was found to display a similar uptake enhancement as does (-)-arctigenin. As a result, the SAR study was conducted utilizing racemic compounds. The structure-activity relationship study led to the discovery of key substitution patterns on the lactone motif that govern 2-deoxyglucose uptake activities. The results show that replacement of the para-hydroxyl group of the C-2 benzyl moiety of arctigenin by Cl has a pronounced effect on uptake activity. Specifically, analogue 2p, which contains the p-Cl substituent, stimulates glucose uptake and fatty acid oxidation in L6 myotubes.

Enantioselective synthesis of natural dibenzylbutyrolactone lignans (-)-enterolactone, (-)-hinokinin, (-)-pluviatolide, (-)-enterodiol, and furofuran lignan (-)-eudesmin via tandem conjugate addition to γ-alkoxybutenolides1,2

A general and efficient method is described for the asymmetric synthesis of a variety of liguans. 5-(Menthyloxy)-2(5H)-furanones 5 proved to be excellent chiral synthons in this respect and could be transformed with complete stereoselectivity into a number of lignans. The addition of lithiated dithianes 7 to enantiomerically pure butenolides 5 was followed by quenching of the resulting lactone enolate anions with a benzylbromide (9) or with an aldehyde (6). This tandem addition quenching procedure gave the diastereomerically pure adducts 11, 26, or 27 in 50-67% yield, with a carbon skeleton as found in most natural lignans. As examples of the wide applicability of this method, the syntheses of the enantiomerically pure natural lignans (-)-hinokinin (23b), (-)-enterolactone (24a), (-)-pluviatolide (24c), and (-)-enterodiol (25) in overall yields of 29-37% from 5a and (-)eudesmin (30) in 16% overall yield from 5b are described.